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Adding mycotoxin detoxifying agents to feed contaminated with mycotoxins is 
commonly used and seems to be the most promising way of counteracting the 
harmful effects of mycotoxins. The European Food Safety Authority (EFSA) 
stipulates that the interaction of these products with oral absorption of drugs and 
nutrients should be investigated. The binding of drugs by these products in the 
gastro-intestinal tract could lead to subtherapeutic plasma and tissue 
concentrations and enhanced microbial resistance. Nevertheless, only few 
literature is available and no models are present to evaluate these possible 
interactions. Therefore, the goal of this study was to develop an in vitro and in 
vivo model for safety testing of these products. The interaction between bentonite 
and tylosin was investigated as a possible interaction was described previously. In 
addition, a commercially available detoxifying agent (gluco-mannan, GMA) was 
tested.  
First, in vitro trials were carried out. Intestinal porcine epithelial cells (IPEC-J2) 
were cultivated on Transwell® cell culture inserts until differentiation (21 days). 
Tylosin (Tylan® Soluble, Elanco, Belgium) (20 µg/mL) was added to the 
basolateral compartment with or without addition of a mycotoxin detoxifying 
agent (bentonite or gluco-mannan (GMA), 1 mg/mL) for 48 h. To determine the 
safety of bentonite and GMA towards adsorption of tylosin, several parameters 
were evaluated: cellular viability by means of a neutral red assay, cellular 
integrity based on the trans-epithelial electrical resistance (TEER) and passage 
through the monolayer by quantification of tylosin in the apical compartment 
using LC-MS/MS. No differences were found in viability or TEER between groups, 
indicating that the tylosin, bentonite or GMA concentration applied was not 
cytotoxic. Quantification of tylosin in the apical compartment showed a significant 
lower passage of tylosin due to binding to bentonite. Apical tylosin concentrations 
of GMA treated inserts did not differ from controls. 
Next, these findings were evaluated by an in vivo model. Tylosin (24 mg/kg BW) 
was administered as a single intra-crop bolus to broiler chickens (n=8), with or 
without a mycotoxin detoxifying agent (bentonite or GMA, 1 mg/kg BW). Blood 
was withdrawn at several time points after bolus administration and plasma 
concentrations of tylosin were determined. Plasma concentration-time profiles 
were evaluated and several pharmacokinetic parameters were compared to the 
control group in order to evaluate the interaction between tylosin and 
bentonite/GMA. Plasma concentrations of tylosin were significantly lower after 
bolus administration of tylosin and bentonite, compared to the control group. No 
interaction between tylosin and GMA was found. These in vivo results confirm our 
in vitro findings. 
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